Lindsley Lab

Education

Albion College, 2011
B.A. Chemistry

University Of Michigan, 2016
Ph.D. Medicinal Chemistry

Biosketch and Research Interests

Aaron earned his PhD in medicinal chemistry (organic synthesis focus) from the University of Michigan in 2016, working on the synthesis of mixed efficacy opioid ligands under the direction of Dr. Henry Mosberg.

Aaron joined the Lindsley lab as a Post Doc in 2016, and is currently working on the synthesis of positive allosteric modulators (PAMs) for the muscarinic acetylcholine receptor M5.

Aaron’s research interests are in medicinal chemistry, particularly the development of therapeutics for CNS disorders, and organic synthesis.

Selected Publications

Turkett, J.A.; Ringuette, A.E.; Lindsley, C.W.; Bender, A.M. ‘Synthesis of Substituted 6,7-Dihydro-5H-pyrrolo[2,3-c]pyridazines/pyrazines via Catalyst-Free Tandem Hydroamination–Aromatic Substitution’ Journal of Organic Chemistry (2020); XX(XX): XXX-XXX. {DOI: 10.1021/acs.joc.9b03463; PMID: 32227869}

Bender, A.M.; Cho, H.P.; Nance, K.D.; Lingenfelter, K.S.; Luscombe, V.B.; Gentry, P.R.; Voigtritter, K.; Berizzi, A.E.; Sexton, P.M.; Langmead, C.J.; Christopoulos, A.; Locuson, C.W.; Bridges, T.M.; Chang, S.; O’Neill, J.C.; Zhan, X.; Niswender, C.M.; Jones, C.J.; Conn, P.J.; Lindsley, C.W. ‘Discovery and Optimization of Potent and CNS Penetrant M5-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold’ ACS Chemical Neuroscience (2018); 9(7): 1572-1581. {DOI: 10.1021/acschemneuro.8b00126; PMID: 29678111}

Bender, A.M.; Chopko, T.C..; Bridges, T.M.; Lindsley, C.W. ‘Preparation of Unsymmetrical 1,2,4,5-Tetrazines via a Mild Suzuki Cross-Coupling Reaction’ Organic Letters (2017); 19(20): 5693-5696. {DOI: 10.1021/acs.orglett.7b02868; PMID: 28976768}

Bender, A.M.; Griggs, N.W.; Anand, J.P.; Traynor, J.R.; Jutkiewicz, E.M.; Mosberg, H.I. ‘Asymmetric Synthesis and in Vitro and in Vivo Activity of Tetrahydroquinolines Featuring a Diverse Set of Polar Substitutions at the 6 Position as Mixed-Efficacy μ Opioid Receptor/δ Opioid Receptor Ligands’ ACS Chemical Neuroscience (2015); 6(8): 1428-1435. {DOI: 10.1021/acschemneuro.5b00100}